<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85021">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01998412</url>
  </required_header>
  <id_info>
    <org_study_id>M-01-12-001</org_study_id>
    <nct_id>NCT01998412</nct_id>
  </id_info>
  <brief_title>Iluvien Registry Safety Study</brief_title>
  <acronym>IRISS</acronym>
  <official_title>An Open Label, Registry Study of the Safety of IluvienÂ® 190 Micrograms Intravitreal Implant in Applicator</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alimera Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alimera Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will include any patient treated with Iluvien at designated sites in European
      countries where marketing authorization has been granted in order to obtain broader safety
      and usage information.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Number of participants with adverse events.</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Chronic Diabetic Macular Oedema Considered Insufficiently Responsive to Available Therapies</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with vision impairment associated with chronic diabetic macular oedema considered
        insufficiently responsive to available therapies that were selected to be treated with an
        intravitreal implant of ILUVIEN.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient treated with Iluvien under this protocol will be included in the study.

        Exclusion Criteria:

          -  Patients/Guardians who are unable to understand and sign the Informed Consent will be
             excluded from the study.

        Retrospective Enrollment Criteria

        Patients treated with ILUVIEN prior to study initiation may be included provided they
        satisfy the inclusion and exclusion criteria, where applicable, as well as, the following
        requirements:

          1. The site is allowed to enroll a patient who was treated with ILUVIEN no more than 36
             months prior to bringing the patient in for their first study visit.

          2. The eligible patient must meet the data requirements as specified in the protocol,
             i.e., baseline data collected within 7 days prior to treatment with ILUVIEN and
             additional data subsequently collected approximately every 6 months thereafter until
             enrolment into the study.

          3. The eligible patient must be enrolled at least one year prior to the planned end of
             the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrew Joyson</last_name>
    <phone>+44 1252 354 026</phone>
    <email>Andrew.Joyson@alimerasciences.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Joyson</last_name>
      <phone>+44 1252 354 026</phone>
      <email>Andrew.Joyson@alimerasciences.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 28, 2016</lastchanged_date>
  <firstreceived_date>November 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
